XtalPi Receives Further $19 Million Under Drug Discovery Agreement With DoveTree
MT Newswires Live
May 28
XtalPi Holdings (HKG:2228) said it received a further $19 million payment from DoveTree Medicines under an AI-driven drug discovery services agreement, according to a Wednesday filing with the Hong Kong bourse.
The bio-tech platform's shares gained over 3% recent trade.
The firm had previously agreed to use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas that would then be licensed to DoveTree.
XtalPi received an upfront payment of $51 million at the time and is eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.